Raptiva RA trials halted
Executive Summary
Genentech and Xoma cease development of Raptiva in rheumatoid arthritis after Phase II trials fail to show "overall net benefit," companies say May 12. Raptiva (efalizumab, formerly Xanelim) BLA for once-weekly treatment of psoriasis was filed Dec. 23; the anti-CD11a monoclonal antibody is in Phase II for psoriatic arthritis...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.